Chugai Pharmaceutical Co., Ltd. (TYO:4519)
Japan
· Delayed Price · Currency is JPY 7,940.00
+495.00 (6.65%)
Apr 28, 2026, 3:30 PM JST
Chugai Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,109,658 | 1,077,803 | 997,901 | 974,493 | 1,039,247 | 802,836 | Upgrade
|
| Other Revenue | 181,571 | 180,138 | 172,710 | 136,874 | 220,699 | 196,923 | Upgrade
|
| Revenue | 1,291,229 | 1,257,941 | 1,170,611 | 1,111,367 | 1,259,946 | 999,759 | Upgrade
|
| Revenue Growth (YoY) | 5.66% | 7.46% | 5.33% | -11.79% | 26.02% | 27.04% | Upgrade
|
| Cost of Revenue | 368,657 | 363,690 | 339,409 | 413,306 | 476,251 | 338,147 | Upgrade
|
| Gross Profit | 922,572 | 894,251 | 831,202 | 698,061 | 783,695 | 661,612 | Upgrade
|
| Selling, General & Admin | 122,125 | 116,461 | 110,098 | 112,580 | 100,760 | 102,416 | Upgrade
|
| Research & Development | 188,558 | 187,598 | 181,440 | 174,868 | 149,626 | 137,299 | Upgrade
|
| Other Operating Expenses | -351 | -8,641 | -2,339 | -28,561 | - | - | Upgrade
|
| Operating Expenses | 310,332 | 295,418 | 289,199 | 258,887 | 250,386 | 239,715 | Upgrade
|
| Operating Income | 612,240 | 598,833 | 542,003 | 439,174 | 533,309 | 421,897 | Upgrade
|
| Interest Expense | -207 | -207 | 5 | -27 | -61 | -48 | Upgrade
|
| Interest & Investment Income | - | - | 1,027 | 4,674 | 52 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1,433 | -820 | -1 | - | -2,134 | -2,464 | Upgrade
|
| Pretax Income | 622,174 | 597,806 | 543,034 | 443,821 | 531,166 | 419,385 | Upgrade
|
| Income Tax Expense | 169,978 | 163,794 | 155,717 | 118,349 | 156,737 | 116,390 | Upgrade
|
| Earnings From Continuing Operations | 452,196 | 434,012 | 387,317 | 325,472 | 374,429 | 302,995 | Upgrade
|
| Net Income | 452,196 | 434,012 | 387,317 | 325,472 | 374,429 | 302,995 | Upgrade
|
| Net Income to Common | 452,196 | 434,012 | 387,317 | 325,472 | 374,429 | 302,995 | Upgrade
|
| Net Income Growth | 10.25% | 12.06% | 19.00% | -13.08% | 23.58% | 41.10% | Upgrade
|
| Shares Outstanding (Basic) | 1,646 | 1,646 | 1,645 | 1,645 | 1,645 | 1,644 | Upgrade
|
| Shares Outstanding (Diluted) | 1,646 | 1,646 | 1,646 | 1,645 | 1,645 | 1,645 | Upgrade
|
| Shares Change (YoY) | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | Upgrade
|
| EPS (Basic) | 274.77 | 263.73 | 235.39 | 197.83 | 227.64 | 184.29 | Upgrade
|
| EPS (Diluted) | 274.77 | 263.72 | 235.36 | 197.80 | 227.57 | 184.17 | Upgrade
|
| EPS Growth | 10.25% | 12.05% | 18.99% | -13.08% | 23.57% | 41.09% | Upgrade
|
| Free Cash Flow | 374,774 | 310,007 | 397,185 | 337,977 | 181,487 | 213,657 | Upgrade
|
| Free Cash Flow Per Share | 227.73 | 188.37 | 241.36 | 205.40 | 110.30 | 129.87 | Upgrade
|
| Dividend Per Share | 122.000 | 122.000 | 98.000 | 80.000 | 78.000 | 76.000 | Upgrade
|
| Dividend Growth | 24.49% | 24.49% | 22.50% | 2.56% | 2.63% | 38.18% | Upgrade
|
| Gross Margin | 71.45% | 71.09% | 71.01% | 62.81% | 62.20% | 66.18% | Upgrade
|
| Operating Margin | 47.41% | 47.60% | 46.30% | 39.52% | 42.33% | 42.20% | Upgrade
|
| Profit Margin | 35.02% | 34.50% | 33.09% | 29.29% | 29.72% | 30.31% | Upgrade
|
| Free Cash Flow Margin | 29.03% | 24.64% | 33.93% | 30.41% | 14.40% | 21.37% | Upgrade
|
| EBITDA | 638,876 | 631,368 | 573,668 | 470,914 | 564,743 | 452,765 | Upgrade
|
| EBITDA Margin | 49.48% | 50.19% | 49.01% | 42.37% | 44.82% | 45.29% | Upgrade
|
| D&A For EBITDA | 26,636 | 32,535 | 31,665 | 31,740 | 31,434 | 30,868 | Upgrade
|
| EBIT | 612,240 | 598,833 | 542,003 | 439,174 | 533,309 | 421,897 | Upgrade
|
| EBIT Margin | 47.41% | 47.60% | 46.30% | 39.52% | 42.33% | 42.20% | Upgrade
|
| Effective Tax Rate | 27.32% | 27.40% | 28.68% | 26.67% | 29.51% | 27.75% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.